May 14, 2009 (FinancialWire) — Professor Paolo Pozzilli, head of the Department of Diabetes and Endocrinology at University Campus Bio-Medico, Rome, Italy and one of the Generex Biotechnology Corp.’s (NASDAQ: GNBT) research clinicians, gave a lecture on the company’s proprietary oral insulin spray product Generex Oral-lyn(tm) at the Hamad General Hospital in the state of Qatar.

Over 30 diabetologists, endocrinologists and hospital department heads attended the lecture entitled, “Buccal Spray Insulin for the Treatment of Diabetes and Impaired Glucose Tolerance.”

Generex Oral-lyn(tm) (buccal insulin spray) is a liquid formulation of human recombinant insulin which is delivered to the buccal mucosa by way of the company’s proprietary RapidMist(tm) device.

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) web site (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Free annual reports for companies mentioned in the news are available through the Free Annual Reports Service (http://investrend.ar.wilink.com/?level=279).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.